U.S. Nuclear Medicine MarketU.S. Nuclear Medicine Market Is Set To Reach 3.58 USD Billion By 2032, Growing At A CAGR Of 21.2
U.S. Nuclear Medicine Market by Type (Diagnostic Radiopharmaceuticals {PET Radiopharmaceuticals [FDG-PET/18F, 68Ga, 68Cu, 11C, Others], SPECT Radiopharmaceuticals [Technetium-99m, Iodine-123, Xenon-133, Thallium-201, Others]}, Therapeutic Radiopharmaceuticals), by Application (Neurology, Cardiology, Oncology, Others), by End-user (Hospitals & Clinics, Diagnostic Centers, Others), by Forecast 2024-2032
Base Year: 2023
120 Pages
U.S. Nuclear Medicine Market Is Set To Reach 3.58 USD Billion By 2032, Growing At A CAGR Of 21.2
Key Insights
The U.S. Nuclear Medicine Market size was valued at USD 3.58 USD Billion in 2023 and is projected to reach USD 13.75 USD Billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. Nuclear Medicine is the branch of medicine that uses small amounts of radioactive substances or radiotracers to diagnose or treat various diseases; techniques include Positron emission tomography (PET), Single photon emission computed tomography (SPECT), and radionuclide therapy. Some of the attractive features are high-resolution imaging, early diagnosis, and personalized therapy. Specialization covers oncology, cardiology, and neurology, it improves the assessment of organ function and cellular processes. Current trends in the US market include improvement in molecular radiopharmaceuticals, epidemiological changes, and applications of hybrid imaging. Also, advancements in technologies and increased spending on healthcare facilities make the sector more developed and with better diagnoses.
U.S. Nuclear Medicine Trends
- Rising demand for personalized medicine in diagnostic and therapeutic applications
- Growing adoption of hybrid imaging technologies for accurate disease diagnosis
- Increasing focus on theranostics for targeted cancer treatment
Driving Forces: What's Propelling the U.S. Nuclear Medicine Market
- Rising incidence of cancer and cardiovascular diseases
- Growing demand for early and accurate disease diagnosis
- Technological advancements in radiopharmaceutical development
- Increasing healthcare spending on advanced medical imaging modalities
Challenges and Restraints in the U.S. Nuclear Medicine Market
- Limited reimbursement for nuclear medicine procedures
- Concerns associated with radiation exposure
- Stringent regulatory requirements for radiopharmaceutical production and use
- Availability of alternative imaging modalities, such as MRI and CT
Emerging Trends in U.S. Nuclear Medicine
- Development of novel radiopharmaceuticals for targeted therapies
- Integration of Artificial intelligence and Machine learning in nuclear Medicine Imaging
- Growing focus on personalized medicine and companion diagnostics
Growth Catalysts in the U.S. Nuclear Medicine Industry
- Government initiatives to promote nuclear medicine research and development
- Increasing investment in nuclear medicine infrastructure
- Collaboration between pharmaceutical companies and research institutions
Market Segmentation: U.S. Nuclear Medicine Analysis
Type:
- Diagnostic Radiopharmaceuticals
- PET Radiopharmaceuticals
- SPECT Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
Application:
- Neurology
- Cardiology
- Oncology
- Others
End-user:
- Hospitals & Clinics
- Diagnostic Centers
- Others
Leading Players in the U.S. Nuclear Medicine Market
- Lantheus (U.S.)
- Cardinal Health (U.S.)
- Bracco (U.S.)
- GE Healthcare (General Electric Company) (U.S.)
- CURIUM (France)
- Bayer AG (Germany)
- RLS, Inc. (U.S.)
Significant Developments in the U.S. Nuclear Medicine Sector
- June 2023: SpectronRx and RLS (USA), Inc. announced an agreement to enhance the supply of radiopharmaceuticals.
- May 2023: TG Imaging Solutions acquired Digirad Health, providing mobile nuclear medicine camera services.
- September 2021: Gurnick Academy launched a nuclear medicine technologist program in California.
Comprehensive Coverage U.S. Nuclear Medicine Market Report
- In-depth examination of macroeconomic and healthcare industry trends impacting the nuclear medicine landscape
- Granular market segmentation by type (e.g., diagnostic, therapeutic), application (e.g., oncology, cardiology), and end-user (e.g., hospitals, clinics)
- Detailed profiles of key players, including market share analysis, recent developments, and competitive strategies
- Analysis of emerging technologies, including molecular imaging and targeted radionuclide therapy
- Assessment of regulatory and reimbursement policies affecting market growth
- Exploration of key challenges and opportunities facing the industry
- Comprehensive forecast of market size and growth rates from 2023 to 2030, segmented by region and key segments
Regional Insight
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain)
- Asia Pacific (China, Japan, India, South Korea)
- Latin America (Brazil, Argentina, Colombia)
- Middle East and Africa (Saudi Arabia, UAE, South Africa)
Pricing Analysis
- Price comparison of radiopharmaceuticals across different regions
- Pricing strategies adopted by leading players
- Impact of reimbursement policies on pricing
Import And Export Analysis
- Analysis of major import and export trends
- Key import and export destinations
- Trade regulations and tariffs
Segmentation
- Market segmentation by application, end-user, and technology
- Market size and growth potential for each segment
Patent/Trademark Analysis
- Patent and trademark landscape in the nuclear medicine industry
- Key patents and their impact on market dynamics
- Analysis of intellectual property protection strategies
U.S. Nuclear Medicine Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 21.2% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Growing Prevalence of Chronic Diseases to Augment Market Growth
- 3.3. Market Restrains
- 3.3.1. Lack of Reimbursement for Diagnostic Radiopharmaceuticals May Hamper Market Growth
- 3.4. Market Trends
- 3.4.1. Technological Advancements in Nuclear Imaging Modalities is a Key Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Diagnostic Radiopharmaceuticals {PET Radiopharmaceuticals [FDG-PET/18F
- 5.1.2. 68Ga
- 5.1.3. 68Cu
- 5.1.4. 11C
- 5.1.5. Others]
- 5.1.6. SPECT Radiopharmaceuticals [Technetium-99m
- 5.1.7. Iodine-123
- 5.1.8. Xenon-133
- 5.1.9. Thallium-201
- 5.1.10. Others]}
- 5.1.11. Therapeutic Radiopharmaceuticals
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Neurology
- 5.2.2. Cardiology
- 5.2.3. Oncology
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - by End-user
- 5.3.1. Hospitals & Clinics
- 5.3.2. Diagnostic Centers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1.
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. Northeast U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1 Diagnostic Radiopharmaceuticals
- 6.1.2 PET Radiopharmaceuticals (FDG-PET/18F
- 6.1.3 68Ga
- 6.1.4 68Cu
- 6.1.5 11C
- 6.1.6 and Others)
- 6.1.7 SPECT Radiopharmaceuticals (Technetium-99m
- 6.1.8 Iodine-123
- 6.1.9 Xenon-133
- 6.1.10 Thallium-201
- 6.1.11 and Others)
- 6.1.12 Therapeutic Radiopharmaceuticals
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1 Neurology
- 6.2.2 Cardiology
- 6.2.3 Oncology
- 6.2.4 and Others
- 6.3. Market Analysis, Insights and Forecast - By End-user
- 6.3.1 Hospitals & Clinics
- 6.3.2 Diagnostic Centers
- 6.3.3 and Others
- 7. Southeast U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1 Diagnostic Radiopharmaceuticals
- 7.1.2 PET Radiopharmaceuticals (FDG-PET/18F
- 7.1.3 68Ga
- 7.1.4 68Cu
- 7.1.5 11C
- 7.1.6 and Others)
- 7.1.7 SPECT Radiopharmaceuticals (Technetium-99m
- 7.1.8 Iodine-123
- 7.1.9 Xenon-133
- 7.1.10 Thallium-201
- 7.1.11 and Others)
- 7.1.12 Therapeutic Radiopharmaceuticals
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1 Neurology
- 7.2.2 Cardiology
- 7.2.3 Oncology
- 7.2.4 and Others
- 7.3. Market Analysis, Insights and Forecast - By End-user
- 7.3.1 Hospitals & Clinics
- 7.3.2 Diagnostic Centers
- 7.3.3 and Others
- 8. Midwest U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1 Diagnostic Radiopharmaceuticals
- 8.1.2 PET Radiopharmaceuticals (FDG-PET/18F
- 8.1.3 68Ga
- 8.1.4 68Cu
- 8.1.5 11C
- 8.1.6 and Others)
- 8.1.7 SPECT Radiopharmaceuticals (Technetium-99m
- 8.1.8 Iodine-123
- 8.1.9 Xenon-133
- 8.1.10 Thallium-201
- 8.1.11 and Others)
- 8.1.12 Therapeutic Radiopharmaceuticals
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1 Neurology
- 8.2.2 Cardiology
- 8.2.3 Oncology
- 8.2.4 and Others
- 8.3. Market Analysis, Insights and Forecast - By End-user
- 8.3.1 Hospitals & Clinics
- 8.3.2 Diagnostic Centers
- 8.3.3 and Others
- 9. Southwest U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1 Diagnostic Radiopharmaceuticals
- 9.1.2 PET Radiopharmaceuticals (FDG-PET/18F
- 9.1.3 68Ga
- 9.1.4 68Cu
- 9.1.5 11C
- 9.1.6 and Others)
- 9.1.7 SPECT Radiopharmaceuticals (Technetium-99m
- 9.1.8 Iodine-123
- 9.1.9 Xenon-133
- 9.1.10 Thallium-201
- 9.1.11 and Others)
- 9.1.12 Therapeutic Radiopharmaceuticals
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1 Neurology
- 9.2.2 Cardiology
- 9.2.3 Oncology
- 9.2.4 and Others
- 9.3. Market Analysis, Insights and Forecast - By End-user
- 9.3.1 Hospitals & Clinics
- 9.3.2 Diagnostic Centers
- 9.3.3 and Others
- 10. West U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1 Diagnostic Radiopharmaceuticals
- 10.1.2 PET Radiopharmaceuticals (FDG-PET/18F
- 10.1.3 68Ga
- 10.1.4 68Cu
- 10.1.5 11C
- 10.1.6 and Others)
- 10.1.7 SPECT Radiopharmaceuticals (Technetium-99m
- 10.1.8 Iodine-123
- 10.1.9 Xenon-133
- 10.1.10 Thallium-201
- 10.1.11 and Others)
- 10.1.12 Therapeutic Radiopharmaceuticals
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1 Neurology
- 10.2.2 Cardiology
- 10.2.3 Oncology
- 10.2.4 and Others
- 10.3. Market Analysis, Insights and Forecast - By End-user
- 10.3.1 Hospitals & Clinics
- 10.3.2 Diagnostic Centers
- 10.3.3 and Others
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 Lantheus (U.S.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Cardinal Health (U.S.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Bracco (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 GE HealthCare (General Electric Company) (U.S.)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 CURIUM (France)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Bayer AG (Germany)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 RLS Inc. (U.S.)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Advanced Accelerator Applications (Novartis AG) (France)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Nordion (Canada) Inc. (Canada)
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Jubilant Pharma Limited (U.S.)
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.1 Lantheus (U.S.)
List of Figures
- Figure 1: U.S. Nuclear Medicine Market Revenue Breakdown (USD Billion, %) by Product 2023 & 2031
- Figure 2: U.S. Nuclear Medicine Market Value Share (%), by Type 2023 & 2031
- Figure 3: U.S. Nuclear Medicine Market Value Share (%), by Application 2023 & 2031
- Figure 4: U.S. Nuclear Medicine Market Value Share (%), by End-user 2023 & 2031
- Figure 5: U.S. Nuclear Medicine Market Share (%) by Company 2023
List of Tables
- Table 1: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 2: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Type 2018 & 2031
- Table 3: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Application 2018 & 2031
- Table 4: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Application 2018 & 2031
- Table 5: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 6: U.S. Nuclear Medicine Market Volume K Tons Forecast, by End-user 2018 & 2031
- Table 7: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 8: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Region 2018 & 2031
- Table 9: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 10: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Type 2018 & 2031
- Table 11: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Application 2018 & 2031
- Table 12: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Application 2018 & 2031
- Table 13: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 14: U.S. Nuclear Medicine Market Volume K Tons Forecast, by End-user 2018 & 2031
- Table 15: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 16: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Region 2018 & 2031
- Table 17: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 18: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Type 2018 & 2031
- Table 19: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Application 2018 & 2031
- Table 20: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Application 2018 & 2031
- Table 21: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 22: U.S. Nuclear Medicine Market Volume K Tons Forecast, by End-user 2018 & 2031
- Table 23: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 24: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Country 2018 & 2031
- Table 25: Northeast U.S. Nuclear Medicine Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 26: Northeast U.S. Nuclear Medicine Market Volume (K Tons) Forecast, by Application 2018 & 2031
- Table 27: Southeast U.S. Nuclear Medicine Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 28: Southeast U.S. Nuclear Medicine Market Volume (K Tons) Forecast, by Application 2018 & 2031
- Table 29: Midwest U.S. Nuclear Medicine Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 30: Midwest U.S. Nuclear Medicine Market Volume (K Tons) Forecast, by Application 2018 & 2031
- Table 31: Southwest U.S. Nuclear Medicine Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 32: Southwest U.S. Nuclear Medicine Market Volume (K Tons) Forecast, by Application 2018 & 2031
- Table 33: West U.S. Nuclear Medicine Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 34: West U.S. Nuclear Medicine Market Volume (K Tons) Forecast, by Application 2018 & 2031
- Table 35: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 36: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Type 2018 & 2031
- Table 37: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Application 2018 & 2031
- Table 38: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Application 2018 & 2031
- Table 39: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 40: U.S. Nuclear Medicine Market Volume K Tons Forecast, by End-user 2018 & 2031
- Table 41: U.S. Nuclear Medicine Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 42: U.S. Nuclear Medicine Market Volume K Tons Forecast, by Country 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 21.2% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
